

A Double Blind, Randomised, Placebo Controlled Study of Farlutal in the Treatment of Weight Loss in Patients Undergoing Radiotherapy for Head and Neck Cancer

Submission date 19/08/2002	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
Registration date 19/08/2002	Overall study status Completed	<input type="checkbox"/> Protocol
Last Edited 03/03/2008	Condition category Cancer	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr - -

Contact details

UKCCCR Register Co-ordinator
MRC Clinical Trials Unit
222 Euston Road
London
United Kingdom
NW1 2DA

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

Study information

Scientific Title

Study objectives

Not provided at time of registration

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Randomised controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Not specified

Study type(s)

Not Specified

Participant information sheet

Health condition(s) or problem(s) studied

Head and Neck Cancer

Interventions

1. Group A: Oral medroxyprogesterone acetate 500 mg twice daily for a maximum of 12 weeks
2. Group B: Placebo tablets twice daily for a maximum of 12 weeks

Intervention Type

Other

Phase

Not Specified

Primary outcome measure

Not provided at time of registration

Secondary outcome measures

Not provided at time of registration

Overall study start date

19/08/2000

Completion date

19/08/2005

Eligibility

Key inclusion criteria

1. Aged >18 years
2. Squamous cell carcinoma of the head and neck
3. Not known to have or suspected of having early breast cancer
4. No known hypersensitivity to medroxyprogesterone acetate
5. No medical contraindications to treatment

Participant type(s)

Patient

Age group

Not Specified

Lower age limit

18 Years

Sex

Not Specified

Target number of participants

Not provided at time of registration

Key exclusion criteria

Not provided at time of registration

Date of first enrolment

19/08/2000

Date of final enrolment

19/08/2005

Locations

Countries of recruitment

England

Italy

United Kingdom

Study participating centre
UKCCCR Register Co-ordinator
London
United Kingdom
NW1 2DA

Sponsor information

Organisation
Farmitalia Carlo Erba (Italy)

Sponsor details

-

-

Italy

-

Sponsor type
Industry

ROR
<https://ror.org/03htt2d69>

Funder(s)

Funder type
Not defined

Funder Name
Not provided at time of registration.

Results and Publications

Publication and dissemination plan
Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration